Bridget F. Koontz, MD | Authors


Results of a Phase II Study of LHRH Therapy in High-Risk Prostate Cancer

March 15, 2018

Bridget F. Koontz, MD, associate professor of radiation oncology, Duke Cancer Institute, discusses a single-arm, phase II trial of 6 months of concurrent androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.